Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Transl Med ; 13(625): eabg7565, 2021 12 22.
Article in English | MEDLINE | ID: mdl-34936383

ABSTRACT

Chimeric antigen receptor (CAR) T cells induce durable responses in patients with refractory hematological tumors. However, low CAR T cell activity, poor engraftment, or short in-patient persistence can lead to tumor progression or relapse. Furthermore, excessive CAR T cell expansion and activation can result in life-threatening cytokine release syndrome (CRS). Thus, in-patient control of the CAR T cell population is essential. Interleukin-2 (IL-2) is a critical cytokine for T cell proliferation and effector function, but its clinical use is limited by immune-mediated toxicity. Here, we report on an orthogonal IL-2 receptor and ligand system that enables specific in vivo control of CAR T cell expansion and activation, wherein an orthogonal human IL-2 (STK-009) selectively pairs with an orthogonal human IL-2Rß (hoRb) expressed on CAR T cells. STK-009 expands hoRb-expressing CAR T cells in the presence and absence of tumor antigen and maintains the presence of stem cell memory T cells (TSCM) and effector T cells. In preclinical models of human CAR-refractory lymphoma, STK-009 treatment resulted in systemic and intratumoral expansion and activation of hoRb-expressing anti­CD19-CD28ζ CAR T cells (SYNCAR). The orthogonal IL-2 receptor/ligand system delivers complete responses in large subcutaneous lymphomas, even with substantially reduced CAR T cell doses, by selectively expanding and activating CAR T cells in vivo. STK-009 withdrawal allowed normal CAR T cell contraction, thereby limiting CRS induced by tumor antigen­specific T cell activation. These data suggest that the orthogonal IL-2 receptor/ligand system provides the in vivo control necessary to maximize efficacy of CAR T therapies.


Subject(s)
Interleukin-2 , Lymphoma , Antigens, CD19 , Humans , Immunotherapy, Adoptive , Lymphoma/therapy , Neoplasm Recurrence, Local/therapy , Receptors, Antigen, T-Cell , T-Lymphocytes
2.
Cancer Immunol Res ; 6(10): 1199-1211, 2018 10.
Article in English | MEDLINE | ID: mdl-30154083

ABSTRACT

GITR is a costimulatory receptor currently undergoing phase I clinical trials. Efficacy of anti-GITR therapy in syngeneic mouse models requires regulatory T-cell depletion and CD8+ T-cell costimulation. It is increasingly appreciated that immune cell proliferation and function are dependent on cellular metabolism. Enhancement of diverse metabolic pathways leads to different immune cell fates. Little is known about the metabolic effects of GITR agonism; thus, we investigated whether costimulation via GITR altered CD8+ T-cell metabolism. We found activated, GITR-treated CD8+ T cells upregulated nutrient uptake, lipid stores, glycolysis, and oxygen consumption rate (OCR) in vitro Using MEK, PI3Kδ, and metabolic inhibitors, we show increased metabolism is required, but not sufficient, for GITR antibody (DTA-1)-induced cellular proliferation and IFNγ production. In an in vitro model of PD-L1-induced CD8+ T-cell suppression, GITR agonism alone rescued cellular metabolism and proliferation, but not IFNγ production; however, DTA-1 in combination with anti-PD-1 treatment increased IFNγ production. In the MC38 mouse tumor model, GITR agonism significantly increased OCR and IFNγ and granzyme gene expression in both tumor and draining lymph node (DLN) CD8+ T cells ex vivo, as well as basal glycolysis in DLN and spare glycolytic capacity in tumor CD8+ T cells. DLN in GITR-treated mice showed significant upregulation of proliferative gene expression compared with controls. These data show that GITR agonism increases metabolism to support CD8+ T-cell proliferation and effector function in vivo, and that understanding the mechanism of action of agonistic GITR antibodies is crucial to devising effective combination therapies. Cancer Immunol Res; 6(10); 1199-211. ©2018 AACR.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Colonic Neoplasms/immunology , Cytokines/immunology , Glucocorticoid-Induced TNFR-Related Protein/agonists , Glucocorticoid-Induced TNFR-Related Protein/immunology , Animals , Antibodies/pharmacology , B7-H1 Antigen/immunology , CD8-Positive T-Lymphocytes/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Disease Models, Animal , Mice, Inbred C57BL
3.
J Biol Chem ; 285(27): 20850-9, 2010 Jul 02.
Article in English | MEDLINE | ID: mdl-20444694

ABSTRACT

The development of bispecific antibodies as therapeutic agents for human diseases has great clinical potential, but broad application has been hindered by the difficulty of identifying bispecific antibody formats that exhibit favorable pharmacokinetic properties and ease of large-scale manufacturing. Previously, the development of an antibody technology utilizing heavy chain knobs-into-holes mutations and a single common light chain enabled the small-scale generation of human full-length bispecific antibodies. Here we have extended the technology by developing a two-part bispecific antibody discovery strategy that facilitates proof-of-concept studies and clinical candidate antibody generation. Our scheme consists of the efficient small-scale generation of bispecific antibodies lacking a common light chain and the hinge disulfides for proof-of-concept studies coupled with the identification of a common light chain bispecific antibody for large-scale production with high purity and yield. We have applied this technology to generate a bispecific antibody suitable for development as a human therapeutic. This antibody directly inhibits the activation of the high affinity IgE receptor FcepsilonRI on mast cells and basophils by cross-linking FcepsilonRI with the inhibitory receptor FcgammaRIIb, an approach that has strong therapeutic potential for asthma and other allergic diseases. Our approach for producing human bispecific full-length antibodies enables the clinical application of bispecific antibodies to a validated therapeutic pathway in asthma.


Subject(s)
Antibodies, Bispecific/therapeutic use , Receptors, IgE/physiology , Amino Acid Substitution , Animals , Antibodies, Bispecific/genetics , Antibody Specificity , Basophils/immunology , Cell Line, Tumor , Codon/genetics , Enzyme-Linked Immunosorbent Assay , Escherichia coli/genetics , Genes , Glutathione Transferase/genetics , Humans , Immunoglobulin E/genetics , Immunoglobulin E/immunology , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Light Chains/genetics , Mice , Mice, SCID , Passive Cutaneous Anaphylaxis/immunology , Receptors, IgE/antagonists & inhibitors , Receptors, IgE/drug effects , Receptors, IgE/immunology , Receptors, IgG/immunology , Recombinant Proteins/therapeutic use , Retinal Neoplasms/immunology , Retinoblastoma/immunology , Sensitivity and Specificity
4.
J Strength Cond Res ; 20(2): 450-1, 2006 May.
Article in English | MEDLINE | ID: mdl-16686579

ABSTRACT

Offering a college program in exercise science presents challenges when attempting to mainstream credentialed students into the fitness industry, specifically as personal trainers. Unfortunately, today's clubs, regardless of their education or degree, are more interested in hiring personal trainers with specific certifications. With the growing number of available certifications, college students are expected to have a college degree and obtain multiple fitness related certifications before being considered for a personal training position. Is a college graduate still required to obtain a personal training certification? In an effort to have the best qualified individuals training clients, i.e., those with degrees, it becomes necessary to know what certification is the most preferred. The purpose of this study was to impact local college curriculums to increase the marketability of degree recipients upon graduation.


Subject(s)
Certification , Physical Education and Training/standards , Societies , Employment , Fitness Centers , Humans , Massachusetts , Pilot Projects , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...